^
    Back
    Association details:
    Biomarker:BRCA1 mutation + PD-L1 expression
    Cancer:Cholangiocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Onco Targets Ther
    Title:

    Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report

    Excerpt:
    This case report describes a patient with BRCA1-mutated and PD-L1-positive iCCA recurrence and metastases who received olaparib and pembrolizumab….The patient achieved complete response (CR)...Olaparib and pembrolizumab can effectively treat BRCA1-mutated and PD-L1-positive iCCA patients, and adverse effects were largely unobserved.
    DOI:
    10.2147/OTT.S250454